DexCom Stock Forecast, Price & News

DexCom's stock was trading at $252.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, DXCM stock has increased by 29.8% and is now trading at $327.72.
View which stocks have been most impacted by COVID-19.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 1 sell rating, 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for DexCom or view MarketBeat's top 5 stock picks.

Wall Street analysts have given DexCom a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but DexCom wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

DexCom is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for DexCom.

DexCom, Inc. (NASDAQ:DXCM) issued its earnings results on Tuesday, October, 27th. The medical device company reported $0.94 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.64 by $0.30. DexCom had a net margin of 12.69% and a return on equity of 27.29%.
View DexCom's earnings history.

DexCom updated its FY 2020 After-Hours earnings guidance on Tuesday, October, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.9-1.9 billion, compared to the consensus revenue estimate of $1.87 billion.

19 brokers have issued 1-year price targets for DexCom's stock. Their forecasts range from $230.00 to $500.00. On average, they expect DexCom's share price to reach $406.22 in the next year. This suggests a possible upside of 24.0% from the stock's current price.
View analysts' price targets for DexCom.

DexCom saw a decline in short interest in October. As of October 30th, there was short interest totaling 2,740,000 shares, a decline of 31.0% from the October 15th total of 3,970,000 shares. Based on an average trading volume of 948,900 shares, the days-to-cover ratio is currently 2.9 days.
View DexCom's Short Interest.

Some companies that are related to DexCom include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), Baxter International (BAX), ResMed (RMD), Hologic (HOLX), Teleflex (TFX), Insulet (PODD), STERIS (STE) and Varian Medical Systems (VAR).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), salesforce.com (CRM), ServiceNow (NOW), The Walt Disney (DIS), The Trade Desk (TTD) and Shopify (SHOP).

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

DexCom's stock is owned by many different institutional and retail investors. Top institutional investors include Morgan Stanley (4.29%), Jennison Associates LLC (2.85%), Sands Capital Management LLC (2.43%), Blair William & Co. IL (1.09%), Nuveen Asset Management LLC (0.84%) and Great West Life Assurance Co. Can (0.69%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman and Steven Robert Pacelli.
View institutional ownership trends for DexCom.

DXCM stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Sei Investments Co., First Hawaiian Bank, Columbus Circle Investors, First Trust Advisors LP, Cubist Systematic Strategies LLC, Dowling & Yahnke LLC, and Massachusetts Financial Services Co. MA. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, and Steven Robert Pacelli.
View insider buying and selling activity for DexCom.

DXCM stock was acquired by a variety of institutional investors in the last quarter, including Great West Life Assurance Co. Can, Sands Capital Management LLC, Point72 Asset Management L.P., Nuveen Asset Management LLC, Jackson Square Partners LLC, Worldquant Millennium Advisors LLC, Charles Schwab Investment Management Inc., and BP PLC.
View insider buying and selling activity for DexCom.

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DXCM stock can currently be purchased for approximately $327.72.

DexCom has a market capitalization of $31.47 billion and generates $1.48 billion in revenue each year. The medical device company earns $101.10 million in net income (profit) each year or $1.84 on an earnings per share basis. DexCom employs 3,900 workers across the globe.

The official website for DexCom is www.dexcom.com.

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]